Want to see FR:BOI full AI Analyst Report?
Top Page
Boiron SA
(BOI)
Select Model
Select Model
Rating:71Outperform
Price Target:
€30.00
▲(16.73% Upside)
Action:Upgraded
Date:08/06/26
The score is driven primarily by solid underlying fundamentals—especially a conservatively leveraged balance sheet and positive cash generation—tempered by weak revenue consistency and a severe reported 2025 revenue contraction. Valuation adds support via a reasonable P/E and strong dividend yield, while technical indicators are broadly neutral with only modest momentum.
Positive Factors
Conservative balance sheet
Very low leverage gives Boiron financial flexibility to fund operations, absorb periods of weaker demand, and support product investment without relying heavily on additional borrowing.
Negative Factors
Severe revenue contraction
A severe reported decline in sales weakens visibility into demand and makes it harder to assess the durability of the company’s earnings, operating scale, and ability to sustain investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage gives Boiron financial flexibility to fund operations, absorb periods of weaker demand, and support product investment without relying heavily on additional borrowing.
Read all positive factors
Boiron SA (BOI) vs. iShares MSCI France ETF (EWQ)
Market Cap
€457.23M
Dividend Yield5.15%
Average Volume (3M)2.04K
Price to Earnings (P/E)14.1
Beta (1Y)0.09
Revenue Growth2.78%
EPS Growth187.96%
CountryFR
Employees2,499
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,545,408
10 Day Avg. Volume1,494
30 Day Avg. Volume2,040
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.35
Price to Sales (P/S)1.06
P/FCF Ratio17.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Boiron SA Business Overview & Revenue Model
Company Description
Boiron S.A. is a global pharmaceutical company specializing in the production and distribution of homeopathic remedies across France, Europe, North America, and other international markets. Its extensive product portfolio encompasses a range of no...
How the Company Makes Money
Boiron makes money primarily by selling its health products—most notably homeopathic medicines—through wholesale and retail distribution networks, with pharmacies as a key channel. Revenue is generated from the commercial sale of packaged remedies...
Boiron SA Financial Statement Overview
Summary
Income Statement
60
Neutral
Balance Sheet
82
Very Positive
Cash Flow
67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 501.11M | 487.56M | 493.25M | 534.24M | 455.20M |
| Gross Profit | 365.73M | 358.76M | 358.08M | 379.73M | 327.62M |
| EBITDA | 66.30M | 45.46M | 73.67M | 91.33M | 78.75M |
| Net Income | 32.64M | 11.34M | 35.83M | 44.67M | 28.56M |
Balance Sheet | |||||
| Total Assets | 602.81M | 576.33M | 590.20M | 789.49M | 770.70M |
| Cash, Cash Equivalents and Short-Term Investments | 79.34M | 64.71M | 74.04M | 250.94M | 234.50M |
| Total Debt | 31.48M | 14.97M | 13.70M | 22.17M | 12.61M |
| Total Liabilities | 210.03M | 198.15M | 198.70M | 232.15M | 238.93M |
| Stockholders Equity | 392.76M | 378.14M | 393.66M | 557.62M | 531.74M |
Cash Flow | |||||
| Free Cash Flow | 29.72M | 33.77M | 27.47M | 41.51M | 13.46M |
| Operating Cash Flow | 53.24M | 42.17M | 45.49M | 60.10M | 33.88M |
| Investing Cash Flow | -23.39M | -18.36M | -22.93M | -15.28M | -11.92M |
| Financing Cash Flow | -24.39M | -27.85M | -198.41M | -28.99M | -22.00M |
Boiron SA Technical Analysis
Neutral
25.70
Price Trends
26.71
Negative
26.81
Negative
26.96
Negative
Market Momentum
-0.19
Negative
47.71
Neutral
74.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BOI, the sentiment is Neutral. The current price of 25.7 is below the 20-day moving average (MA) of 26.00, below the 50-day MA of 26.71, and below the 200-day MA of 26.96, indicating a neutral trend. The MACD of -0.19 indicates Negative momentum. The RSI at 47.71 is Neutral, neither overbought nor oversold. The STOCH value of 74.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:BOI.
Boiron SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | €457.23M | 14.09 | 8.57% | 5.15% | 2.78% | 187.96% | |
65 Neutral | €13.11B | 25.23 | 11.33% | 1.02% | 13.63% | 14.45% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | €549.60M | -3.22 | -152.15% | ― | -27.19% | -117.39% | |
42 Neutral | €68.15M | -17.94 | 6.99% | ― | 9.51% | 73.33% | |
38 Underperform | €741.19M | -3.37 | -119.47% | ― | ― | 41.33% |
* General Sector Average
FR:BOI
Boiron SA
26.20
3.81
17.00%
FR:DBV
DBV Technologies
2.26
0.62
38.05%
FR:IPN
Ipsen
156.40
38.06
32.16%
FR:ALCOX
Nicox SA
0.36
-0.02
-4.56%
FR:VLA
Valneva
2.90
-0.99
-25.49%
FR:AB
AB Science SA
0.71
-0.54
-43.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.